Cleocin Phosphate®

(clindamycin injection, USP) and

(clindamycin injection in 5% dextrose )

To reduce the development of drug-resistant bacteria and maintain the effectiveness of

CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should
be used only to treat or prevent infections that are proven or strongly suspected to be
caused by bacteria.

Sterile Solution is for Intramuscular and Intravenous Use

CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all
antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from
mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of
the colon leading to overgrowth of C. difficile.

Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic antimicrobial
agents are inappropriate, as described in the INDICATIONS AND USAGE section. It
should not be used in patients with nonbacterial infections such as most upper respiratory
tract infections. C. difficile produces toxins A and B which contribute to the development
of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and
mortality, as these infections can be refractory to antimicrobial therapy and may require
colectomy. CDAD must be considered in all patients who present with diarrhea following
antibiotic use. Careful medical history is necessary since CDAD has been reported to
occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.

difficile may need to be discontinued. Appropriate fluid and electrolyte management,
protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation
should be instituted as clinically indicated.

DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a
water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent
of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as
preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)­
chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

1
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]­
1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.

The molecular formula is C18H34CIN208PS and the molecular weight is 504.96.

The structural formula is represented below:

CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use

only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.

CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous

use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of
clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been
added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium
hydroxide and/or hydrochloric acid.

The plastic container is fabricated from a specially designed multilayer plastic, PL 2501.
Solutions in contact with the plastic container can leach out certain of its chemical
components in very small amounts within the expiration period. The suitability of the
plastic has been confirmed in tests in animals according to the USP biological tests for
plastic containers, as well as by tissue culture toxicity studies.

CLINICAL PHARMACOLOGY
Biologically inactive clindamycin phosphate is rapidly converted to active clindamycin.

By the end of short-term intravenous infusion, peak serum levels of active clindamycin
are reached. Biologically inactive clindamycin phosphate disappears rapidly from the
serum; the average elimination half-life is 6 minutes; however, the serum elimination
half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric
patients.

2
After intramuscular injection of clindamycin phosphate, peak levels of active
clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients. Serum
level curves may be constructed from IV peak serum levels as given in Table 1 by
application of elimination half-lives listed above.

Serum levels of clindamycin can be maintained above the in vitro minimum inhibitory
concentrations for most indicated organisms by administration of clindamycin phosphate
every 8 to 12 hours in adults and every 6 to 8 hours in pediatric patients, or by continuous
intravenous infusion. An equilibrium state is reached by the third dose.

The elimination half-life of clindamycin is increased slightly in patients with markedly

reduced renal or hepatic function. Hemodialysis and peritoneal dialysis are not effective
in removing clindamycin from the serum. Dosage schedules need not be modified in the
presence of mild or moderate renal or hepatic disease.

No significant levels of clindamycin are attained in the cerebrospinal fluid even in the
presence of inflamed meninges.

Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39
years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance,
elimination half-life, volume of distribution, and area under the serum concentration-time
curve) after IV administration of clindamycin phosphate. After oral administration of
clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours
(range 3.4–5.1 h) in the elderly compared to 3.2 hours (range 2.1– 4.2 h) in younger
adults. The extent of absorption, however, is not different between age groups and no
dosage alteration is necessary for the elderly with normal hepatic function and normal
(age-adjusted) renal function1.

Serum assays for active clindamycin require an inhibitor to prevent in vitro hydrolysis of
clindamycin phosphate.

Table 1. Average Peak and Trough Serum

Concentrations of Active Clindamycin
After Dosing with Clindamycin Phosphate
Dosage Regimen Peak Trough
mcg/mL mcg/mL
Healthy Adult Males
(Post equilibrium)
600 mg IV in 30 min q6h 10.9 2.0
600 mg IV in 30 min q8h 10.8 1.1
900 mg IV in 30 min q8h 14.1 1.7
600 mg IM q12h* 9.
Pediatric Patients (first dose)*
5–7 mg/kg IV in 1 hour 10
5–7 mg/kg IM 8
3–5 mg/kg IM 4

3
*Data in this group from patients being treated for infection.

Microbiology: Although clindamycin phosphate is inactive in vitro, rapid in vivo

hydrolysis converts this compound to the antibacterially active clindamycin.

Clindamycin has been shown to have in vitro activity against isolates of the following
organisms:

Aerobic gram positive cocci, including:

• Staphylococcus aureus (penicillinase and non-penicillinase producing strains).
When tested by in vitro methods, some staphylococcal strains originally resistant
to erythromycin rapidly develop resistance to clindamycin.
• Staphylococcus epidermidis (penicillinase and non-penicillinase producing
strains). When tested by in vitro methods, some staphylococcal strains originally
resistant to erythromycin rapidly develop resistance to clindamycin.
• Streptococci (except Enterococcus faecalis)
• Pneumococci

Anaerobic gram negative bacilli, including:

• Bacteroides species (including Bacteroides fragilis group and Bacteroides
melaninogenicus group)
• Fusobacterium species

Anaerobic gram positive nonsporeforming bacilli, including:

• Propionibacterium
• Eubacterium
• Actinomyces species

Anaerobic and microaerophilic gram positive cocci, including:

• Peptococcus species
• Peptostreptococcus species
• Microaerophilic streptococci

Clostridia: Clostridia are more resistant than most anaerobes to clindamycin. Most
Clostridium perfringens are susceptible, but other species, e.g., Clostridium sporogenes
and Clostridium tertium are frequently resistant to clindamycin. Susceptibility testing
should be done.

Cross resistance has been demonstrated between clindamycin and lincomycin.

Antagonism has been demonstrated between clindamycin and erythromycin.

In vitro Susceptibility Testing:

Disk diffusion technique-Quantitative methods that require measurement of zone
diameters give the most precise estimates of antibiotic susceptibility. One such

4
procedure2 has been recommended for use with disks to test susceptibility to
clindamycin.

Reports from a laboratory using the standardized single-disk susceptibility test1 with a 2
mcg clindamycin disk should be interpreted according to the following criteria:

Susceptible organisms produce zones of 17 mm or greater, indicating that the tested

organism is likely to respond to therapy.

Organisms of intermediate susceptibility produce zones of 15–16 mm, indicating that the
tested organism would be susceptible if a high dosage is used or if the infection is
confined to tissues and fluids (e.g., urine), in which high antibiotic levels are attained.

Resistant organisms produce zones of 14 mm or less, indicating that other therapy should
be selected.

Standardized procedures require the use of control organisms. The 2 mcg clindamycin
disk should give a zone diameter between 24 and 30 mm for S. aureus ATCC 25923.

Dilution techniques—A bacterial isolate may be considered susceptible if the minimum

inhibitory concentration (MIC) for clindamycin is not more than 1.6 mcg/mL. Organisms
are considered moderately susceptible if the MIC is greater than 1.6 mcg/mL and less
than or equal to 4.8 mcg/mL. Organisms are considered resistant if the MIC is greater
than 4.8 mcg per mL.

The range of MICs for the control strains are as follows:

S. aureus ATCC 29213, 0.06—0.25 mcg/mL.
E. faecalis ATCC 29212, 4.0—16 mcg/mL.

For anaerobic bacteria the minimum inhibitory concentration (MIC) of clindamycin can
be determined by agar dilution and broth dilution (including microdilution) techniques. 3
If MICs are not determined routinely, the disk broth method is recommended for routine
use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE
STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.

INDICATIONS AND USAGE

CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections
caused by susceptible anaerobic bacteria.

CLEOCIN PHOSPHATE products are also indicated in the treatment of serious

infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its
use should be reserved for penicillin-allergic patients or other patients for whom, in the
judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-
associated pseudomembranous colitis, as described in the WARNING box, before
selecting clindamycin the physician should consider the nature of the infection and the
suitability of less toxic alternatives (e.g., erythromycin).

5
Bacteriologic studies should be performed to determine the causative organisms and their
susceptibility to clindamycin.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by

susceptible strains of the designated organisms in the conditions listed below:

Lower respiratory tract infections including pneumonia, empyema, and lung abscess
caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis),
and Staphylococcus aureus.

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus

aureus, and anaerobes.

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess,

pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by

susceptible anaerobic organisms.

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus

faecalis), and susceptible anaerobes.

Bone and joint infections including acute hematogenous osteomyelitis caused by

Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic
bone and joint infections due to susceptible organisms.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of

CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should
be used only to treat or prevent infections that are proven or strongly suspected to be
caused by susceptible bacteria. When culture and susceptibility information are available,
they should be considered in selecting or modifying antibacterial therapy. In the absence
of such data, local epidemiology and susceptibility patterns may contribute to the empiric
selection of therapy.

CONTRAINDICATIONS
This drug is contraindicated in individuals with a history of hypersensitivity to
preparations containing clindamycin or lincomycin.

WARNINGS
See WARNING box.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all
antibacterial agents, including CLEOCIN PHOSPHATE, and may range in severity from

6
mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of
the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as
these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur over
two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.

difficile may need to be discontinued. Appropriate fluid and electrolyte management,
protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation
should be instituted as clinically indicated.

A careful inquiry should be made concerning previous sensitivities to drugs and other
allergens.

This product contains benzyl alcohol as a preservative. Benzyl alcohol has been
associated with a fatal "Gasping Syndrome" in premature infants. (See
PRECAUTIONS–Pediatric Use.)

Usage in Meningitis—Since clindamycin does not diffuse adequately into the

cerebrospinal fluid, the drug should not be used in the treatment of meningitis.

SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY

TREATMENT WITH EPINEPHRINE. OXYGEN AND INTRAVENOUS
CORTICOSTEROIDS SHOULD ALSO BE ADMINISTERED AS INDICATED.

PRECAUTIONS
General
Review of experience to date suggests that a subgroup of older patients with associated
severe illness may tolerate diarrhea less well. When clindamycin is indicated in these
patients, they should be carefully monitored for change in bowel frequency.

CLEOCIN PHOSPHATE products should be prescribed with caution in individuals with

a history of gastrointestinal disease, particularly colitis.

CLEOCIN PHOSPHATE should be prescribed with caution in atopic individuals.

Certain infections may require incision and drainage or other indicated surgical
procedures in addition to antibiotic therapy.

7
The use of CLEOCIN PHOSPHATE may result in overgrowth of nonsusceptible
organisms—particularly yeasts. Should superinfections occur, appropriate measures
should be taken as indicated by the clinical situation.

CLEOCIN PHOSPHATE should not be injected intravenously undiluted as a bolus, but

should be infused over at least 10–60 minutes as directed in the DOSAGE AND
ADMINISTRATION section.

Clindamycin dosage modification may not be necessary in patients with renal disease. In
patients with moderate to severe liver disease, prolongation of clindamycin half-life has
been found. However, it was postulated from studies that when given every eight hours,
accumulation should rarely occur. Therefore, dosage modification in patients with liver
disease may not be necessary. However, periodic liver enzyme determinations should be
made when treating patients with severe liver disease.

Prescribing CLEOCIN PHOSPHATE in the absence of a proven or strongly suspected

bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient
and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Patients should be counseled that antibacterial drugs including CLEOCIN PHOSPHATE
should only be used to treat bacterial infections. They do not treat viral infections (e.g.,
the common cold). When CLEOCIN PHOSPHATE is prescribed to treat a bacterial
infection, patients should be told that although it is common to feel better early in the
course of therapy, the medication should be taken exactly as directed. Skipping doses or
not completing the full course of therapy may (1) decrease the effectiveness of the
immediate treatment and (2) increase the likelihood that bacteria will develop resistance
and will not be treatable by CLEOCIN PHOSPHATE or other antibacterial drugs in the
future.
Diarrhea is a common problem caused by antibiotics which usually ends when the
antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients
can develop watery and bloody stools (with or without stomach cramps and fever) even
as late as two or more months after having taken the last dose of the antibiotic. If this
occurs, patients should contact their physician as soon as possible.

Laboratory Tests
During prolonged therapy periodic liver and kidney function tests and blood counts
should be performed.

Drug Interactions
Clindamycin has been shown to have neuromuscular blocking properties that may
enhance the action of other neuromuscular blocking agents. Therefore, it should be used
with caution in patients receiving such agents.

8
Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
Because of possible clinical significance, the two drugs should not be administered
concurrently.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed with clindamycin to evaluate
carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and
an Ames Salmonella reversion test. Both tests were negative.

Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.1 times
the highest recommended adult human dose based on mg/m2) revealed no effects on
fertility or mating ability.

Pregnancy: Teratogenic effects

Pregnancy category B
Reproduction studies performed in rats and mice using oral doses of clindamycin up to
600 mg/kg/day (2.1 and 1.1 times the highest recommended adult human dose based on
mg/m2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (0.9 and
0.5 times the highest recommended adult human dose based on mg/m2, respectively)
revealed no evidence of teratogenicity.

There are, however, no adequate and well-controlled studies in pregnant women. Because
animal reproduction studies are not always predictive of the human response, this drug
should be used during pregnancy only if clearly needed.

Nursing Mothers
Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/mL
at dosages of 150 mg orally to 600 mg intravenously. Because of the potential for adverse
reactions due to clindamycin in neonates (see Pediatric Use), the decision to discontinue
the drug should be made, taking into account the importance of the drug to the mother.

Pediatric Use
When CLEOCIN PHOSPHATE Sterile Solution is administered to the pediatric
population (birth to 16 years) appropriate monitoring of organ system functions is
desirable.
Usage in Newborns and Infants
This product contains benzyl alcohol as a preservative. Benzyl alcohol has been
associated with a fatal "Gasping Syndrome" in premature infants.
The potential for the toxic effect in the pediatric population from chemicals that may
leach from the single dose premixed IV preparation in plastic has not been evaluated.
Geriatric Use
Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and
over to determine whether they respond differently from younger patients. However,
other reported clinical experience indicates that antibiotic-associated colitis and diarrhea
(due to Clostridium difficile) seen in association with most antibiotics occur more

9
frequently in the elderly (>60 years) and may be more severe. These patients should be
carefully monitored for the development of diarrhea.

Pharmacokinetic studies with clindamycin have shown no clinically important

differences between young and elderly subjects with normal hepatic function and normal
(age-adjusted) renal function after oral or intravenous administration.

ADVERSE REACTIONS
The following reactions have been reported with the use of clindamycin.

Gastrointestinal: Antibiotic-associated colitis (see WARNINGS), pseudomembranous

colitis, abdominal pain, nausea, and vomiting. The onset of pseudomembranous colitis
symptoms may occur during or after antibacterial treatment (see WARNINGS). An
unpleasant or metallic taste occasionally has been reported after intravenous
administration of the higher doses of clindamycin phosphate.

Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed

during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the
most frequently reported of all adverse reactions. Rare instances of erythema multiforme,
some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A
few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction
occurs, the drug should be discontinued. The usual agents (epinephrine, corticosteroids,
antihistamines) should be available for emergency treatment of serious reactions.

Skin and Mucous Membranes: Pruritus, vaginitis, and rare instances of exfoliative
dermatitis have been reported (see Hypersensitivity Reactions).

Liver: Jaundice and abnormalities in liver function tests have been observed during
clindamycin therapy.

Renal: Although no direct relationship of clindamycin to renal damage has been

established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has
been observed in rare instances.

Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been

reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct
etiologic relationship to concurrent clindamycin therapy could be made in any of the
foregoing.

Local Reactions: Pain, induration and sterile abscess have been reported after
intramuscular injection and thrombophlebitis after intravenous infusion. Reactions can be
minimized or avoided by giving deep intramuscular injections and avoiding prolonged
use of indwelling intravenous catheters.

Musculoskeletal: Rare instances of polyarthritis have been reported.

10
Cardiovascular: Rare instances of cardiopulmonary arrest and hypotension have been
reported following too rapid intravenous administration. (See DOSAGE AND
ADMINISTRATION section.)

OVERDOSAGE
Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in
rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice,
convulsions and depression were observed.

Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the
serum.

DOSAGE AND ADMINISTRATION

If diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING
box).

Adults: Parenteral (IM or IV Administration): Serious infections due to aerobic gram-

positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides
fragilis, Peptococcus species and Clostridium species other than Clostridium
perfringens):

600–1200 mg/day in 2, 3 or 4 equal doses.

More severe infections, particularly those due to proven or suspected Bacteroides

fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens:

1200–2700 mg/day in 2, 3 or 4 equal doses.

For more serious infections, these doses may have to be increased. In life-threatening
situations due to either aerobes or anaerobes these doses may be increased. Doses of as
much as 4800 mg daily have been given intravenously to adults. See Dilution and
Infusion Rates section below.

Single intramuscular injections of greater than 600 mg are not recommended.

Alternatively, drug may be administered in the form of a single rapid infusion of the first
dose followed by continuous IV infusion as follows:

To maintain serum Rapid Maintenance

clindamycin infusion infusion
levels rate rate
Above 10 mg/min 0.75 mg/min
4 mcg/mL for 30 min
Above 15 mg/min 1.00 mg/min
5 mcg/mL for 30 min

11
 Above 20 mg/min 1.25 mg/min
6 mcg/mL for 30 min

Neonates (less than 1 month):

15 to 20 mg/kg/day in 3 to 4 equal doses. The lower dosage may be adequate for small
prematures.

Pediatric patients 1 month of age to 16 years: Parenteral (IM or IV) administration: 20 to

40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe
infections. As an alternative to dosing on a body weight basis, pediatric patients may be
dosed on the basis of square meters body surface: 350 mg/m2/day for serious infections
and 450 mg/m2/day for more severe infections.

Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC® Flavored Granules

(clindamycin palmitate hydrochloride) or CLEOCIN HCl® Capsules (clindamycin
hydrochloride) when the condition warrants and at the discretion of the physician.

In cases of β-hemolytic streptococcal infections, treatment should be continued for at

least 10 days.

Dilution and Infusion Rates: Clindamycin phosphate must be diluted prior to IV

administration. The concentration of clindamycin in diluent for infusion should not
exceed 18 mg per mL. Infusion rates should not exceed 30 mg per minute. The usual
infusion dilutions and rates are as follows:

Dose Diluent Time

300 mg 50 mL 10 min
600 mg 50 mL 20 min
900 mg 50–100 mL 30 min
1200 mg 100 mL 40 min

Administration of more than 1200 mg in a single 1-hour infusion is not recommended.

Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.

Dilution and Compatibility: Physical and biological compatibility studies monitored for
24 hours at room temperature have demonstrated no inactivation or incompatibility with
the use of CLEOCIN PHOSPHATE Sterile Solution (clindamycin phosphate) in IV
solutions containing sodium chloride, glucose, calcium or potassium, and solutions
containing vitamin B complex in concentrations usually used clinically. No
incompatibility has been demonstrated with the antibiotics cephalothin, kanamycin,
gentamicin, penicillin or carbenicillin.

12
The following drugs are physically incompatible with clindamycin phosphate: ampicillin
sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and
magnesium sulfate.

The compatibility and duration of stability of drug admixtures will vary depending on
concentration and other conditions. For current information regarding compatibilities of
clindamycin phosphate under specific conditions, please contact the Medical and Drug
Information Unit, Pharmacia & Upjohn Company (Division of Pfizer Inc)..

Physico-Chemical Stability of diluted solutions of CLEOCIN PHOSPHATE

Room temperature: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose
injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass
bottles or minibags, demonstrated physical and chemical stability for at least 16 days at
25°C. Also, 18 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, in
minibags, demonstrated physical and chemical stability for at least 16 days at 25°C.

Refrigeration: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection

5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles or
minibags, demonstrated physical and chemical stability for at least 32 days at 4°C.

IMPORTANT: This chemical stability information in no way indicates that it would be

acceptable practice to use this product well after the preparation time. Good professional
practice suggests that compounded admixtures should be administered as soon after
preparation as is feasible.

Frozen: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%,

sodium chloride injection 0.9%, or Lactated Ringers Injection in minibags demonstrated
physical and chemical stability for at least eight weeks at -10°C.

Frozen solutions should be thawed at room temperature and not refrozen.

DIRECTIONS FOR DISPENSING

Pharmacy Bulk Package — Not for Direct Infusion

The Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only under a
laminar flow hood. Entry into the vial should be made with a small diameter sterile
transfer set or other small diameter sterile dispensing device, and contents dispensed in
aliquots using aseptic technique. Multiple entries with a needle and syringe are not
recommended. AFTER ENTRY USE ENTIRE CONTENTS OF VIAL PROMPTLY.
ANY UNUSED PORTION MUST BE DISCARDED WITHIN 24 HOURS AFTER
INITIAL ENTRY.

DIRECTIONS FOR USE

CLEOCIN PHOSPHATE IV Solution in Galaxy Plastic Container
Premixed CLEOCIN PHOSPHATE IV Solution is for intravenous administration using
sterile equipment. Check for minute leaks prior to use by squeezing bag firmly. If leaks

13
are found, discard solution as sterility may be impaired. Do not add supplementary
medication. Parenteral drug products should be inspected visually for particulate matter
and discoloration prior to administration whenever solution and container permit. Do not
use unless solution is clear and seal is intact.

Caution: Do not use plastic containers in series connections. Such use could result in air
embolism due to residual air being drawn from the primary container before
administration of the fluid from the secondary container is complete.

Preparation for Administration:

1. Suspend container from eyelet support.
2. Remove protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.

Preparation of CLEOCIN PHOSPHATE in ADD-Vantage System—For IV Use

Only. CLEOCIN PHOSPHATE 600 mg and 900 mg may be reconstituted in 50 mL or
100 mL, respectively, of Dextrose Injection 5% or Sodium Chloride Injection 0.9% in the
ADD-diluent container. Refer to separate instructions for ADD-Vantage‡ System.

HOW SUPPLIED
Each mL of CLEOCIN PHOSPHATE Sterile Solution contains clindamycin phosphate
equivalent to 150 mg clindamycin; 0.5 mg disodium edetate; 9.45 mg benzyl alcohol
added as preservative. When necessary, pH is adjusted with sodium hydroxide and/or
hydrochloric acid. CLEOCIN PHOSPHATE is available in the following packages:
25-2 mL vials NDC 0009-0870-26
25-4 mL vials NDC 0009-0775-26
25-6 mL vials NDC 0009-0902-18
5-60 mL Pharmacy Bulk Package NDC 0009-0728-09

CLEOCIN PHOSPHATE is supplied in ADD-Vantage vials as follows:

Total Amount
NDC Vial Size Clindamycin of
Phosphate/vial Diluent
0009-3124-03 25-4 mL 600 mg 50 mL
Vials
0009-3447-03 25-6 mL 900 mg 100 mL
vials

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

CLEOCIN PHOSPHATE IV Solution in Galaxy plastic containers is a sterile solution of

clindamycin phosphate with 5% dextrose. The single dose Galaxy plastic containers are
available as follows:
24-300 mg/50 mL containers NDC 0009-3381-02

14
24-600 mg/50 mL containers NDC 0009-3375-02
24-900 mg/50 mL containers NDC 0009-3382-02

Exposure of pharmaceutical products to heat should be minimized. It is recommended

that Galaxy plastic containers be stored at room temperature (25°C). Avoid temperatures
above 30°C.

ANIMAL TOXICOLOGY
One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose
levels up to 300 mg/kg/day (approximately 1.1 and 3.6 times the highest recommended
adult human dose based on mg/m2, respectively) have shown clindamycin to be well
tolerated. No appreciable difference in pathological findings has been observed between
groups of animals treated with clindamycin and comparable control groups. Rats
receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 2.1 times the
highest recommended adult human dose based on mg/m2) for 6 months tolerated the drug
well; however, dogs dosed at this level (approximately 7.2 times the highest
recommended adult human dose based on mg/m2) vomited, would not eat, and lost
weight.

REFERENCES
1. Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and CLEOCIN Phosphate in an
Aged Population. Upjohn TR 8147-82-9122-021, December 1982.
2. Bauer AW, Kirby WMM, Sherris JC, Turck M; Antibiotic susceptibility testing by a
standardized single disk method. Am. J. Clin. Path., 45:493–496, 1966. Standardized
Disk Susceptibility Test, Federal Register, 37:20527–29, 1972.
3. National Committee for Clinical Lab. Standards. Methods for Antimicrobial
Susceptibility Testing of Anaerobic Bacteria—Second Edition; Tentative Standard.
NCCLS publication M11–T2. Villanova, PA; NCCLS; 1988.

‡ ADD-Vantage is a registered trademark of Abbott Laboratories.

CLEOCIN PHOSPHATE IV Solution in the Galaxy plastic containers is manufactured

for Pfizer Inc by Baxter Healthcare Corporation, Deerfield, IL 60015.

Galaxy® is a trademark of Baxter International, Inc.

Rx only

LAB-0044-6.0
October 2007

15
Cleocin Phosphate®
clindamycin sterile solution for injection, USP
in ADD-Vantage™ Vial

For Intravenous Use Only

NOT FOR INTRAMUSCULAR USE

INSTRUCTIONS FOR USE FOR ADD-VANTAGE SYSTEM—FOR IV USE

ONLY

To Open Diluent Container:

Peel overwrap from the corner and remove container. Some opacity of the plastic due to
moisture absorption during the sterilization process may be observed. This is normal and
does not affect the solution quality or safety. The opacity will diminish gradually.

To Assemble Vial and Flexible Diluent Container:

(Use Aseptic Technique)
1. Remove the protective covers from the top of the vial and the vial port on the diluent
container as follows:
a. To remove the breakaway vial cap, swing the pull ring over the top of the vial and
pull down far enough to start the opening (SEE FIGURE 1.), then pull straight up
to remove the cap. (SEE FIGURE 2.) NOTE: Once the breakaway cap has been
removed, DO NOT ACCESS VIAL WITH SYRINGE.

b. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the
three tie strings, then pull back to remove the cover. (SEE FIGURE 3.)
2. Screw the vial into the vial port until it will go no further. THE VIAL MUST BE
SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2
turn (180°) after the first audible click. (SEE FIGURE 4.) The clicking sound does
not assure a seal; the vial must be turned as far as it will go. NOTE: Once vial is
seated, do not attempt to remove. (SEE FIGURE 4.)

16
3. Recheck the vial to assure that it is tight by trying to turn it further in the direction of
assembly.
4. Label appropriately.

To Prepare Admixture:
1. Squeeze the bottom of the diluent container gently to inflate the portion of the
container surrounding the end of the drug vial.
2. With the other hand, push the drug vial down into the container telescoping the walls
of the container. Grasp the inner cap of the vial through the walls of the container.
(SEE FIGURE 5.)
3. Pull the inner cap from the drug vial. (SEE FIGURE 6.) Verify that the rubber stopper
has been pulled out, allowing the drug and diluent to mix.

4. Mix container contents thoroughly and use within the specified time.

Preparation for Administration: (Use Aseptic Technique)

1. Confirm the activation and admixture of vial contents.
2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as
sterility may be impaired.
3. Close flow control clamp of administration set.
4. Remove cover from outlet port at bottom of container.
5. Insert piercing pin of administration set into port with a twisting motion until the pin
is firmly seated. NOTE: See full directions on administration set carton.

17
6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie
strings. Bend the loop outward to lock it in the upright position, then suspend
container from hanger.
7. Squeeze and release drip chamber to establish proper fluid level in chamber.
8. Open flow control clamp and clear air from set. Close clamp.
9. Attach set to venipuncture device. If device is not indwelling, prime and make
venipuncture.
10. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections.

™ADD-Vantage is a registered trademark of Abbott Laboratories

LAB-0050-2.0
November 2005

18